Clinical Trials
8 trialsNCT07518173 2026-06-04
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07413939 2026-05-11
BREnnA
Hoffmann-La Roche
Phase 2/3 Recruiting
NCT07043725 2026-03-27
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT07377643 2026-02-25
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3 Recruiting
NCT06992882 2025-07-18
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Fudan University
Phase 3 Recruiting
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting
NCT06832904 2025-02-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06217185 2024-02-28
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Hebei Medical University Fourth Hospital
Phase 4 Recruiting